GLP-1 Agonists Show Significant Promise in Reducing Alcohol Use Disorder

Globally, Alcohol Use Disorder (AUD) affects millions, characterized by impaired control over alcohol use, leading to significant health and social consequences. Current pharmacological treatments for AUD have limited efficacy and are often associated with side effects, highlighting an urgent need for novel therapeutic strategies. This study explores the potential of Glucagon-Like Peptide-1 (GLP-1) receptor agonists, typically used for diabetes and obesity, to mitigate alcohol consumption and relapse behaviors in preclinical models of AUD.

The study demonstrated a robust reduction in alcohol consumption and preference in the treated group. Daily alcohol intake was significantly reduced by 55% (p<0.001) in semaglutide-treated rats compared to controls over the 8-week period. The alcohol preference ratio, indicating the proportion of alcohol consumed relative to total fluid intake, decreased by 48% (p<0.001) in the treatment group. Furthermore, semaglutide treatment led to a 32% (p<0.01) reduction in relapse-like drinking behavior following a 2-week abstinence period. Neurochemical analysis revealed that semaglutide attenuated alcohol-induced dopamine release in the nucleus accumbens by 25% (p<0.05), suggesting a modulation of the brain's reward system. The most impactful finding was the 55% reduction in daily alcohol consumption, demonstrating a profound effect of GLP-1 receptor agonists on voluntary alcohol intake in a preclinical model of AUD.